Table 1.
Patients withP. vivaxor mixed (P. vivaxandP. falciparum) malaria treated at IPEC (2005-2011), classified according to therapeutic response
| |
Non-Relapse |
Relapse |
Median [CI 95%] (days) |
p (Log-Rank) |
||
|---|---|---|---|---|---|---|
| n | % | N | % | |||
|
Sample |
32 |
100 |
21 |
100 |
108 [69-NA} |
|
|
Gender |
|
|
|
|
|
|
| Men |
22 |
68.8 |
18 |
85.7 |
104 [68-NA] |
0.16 |
| Women |
10 |
31.2 |
3 |
14.3 |
NA [58-NA] |
|
|
Age range (years) |
|
|
|
|
|
|
| 14-30 |
14 |
43.8 |
14 |
66.7 |
79 [58-NA] |
0.22 |
| 31-50 |
13 |
40.6 |
4 |
19.0 |
369 [108-NA] |
|
| ≥51 |
5 |
15.6 |
3 |
14.3 |
68 [51-NA] |
|
|
Adverse drugs events (ADE)* |
|
|
|
|
|
|
| Yes |
10 |
31.3 |
2 |
9.5 |
NA [58-NA] |
0.20 |
| No |
17 |
53.1 |
12 |
57.1 |
108 [68-NA] |
|
|
Duration of primaquine therapy* |
|
|
|
|
|
|
| Short regimen |
19 |
59.4 |
16 |
76.2 |
79 [65-NA] |
0.34 |
| Long regimen |
10 |
31.3 |
4 |
19.0 |
218 [104-NA] |
|
|
Primaquine total dose adjusted by weight* |
|
|
|
|
|
|
| Yes (≥ 3.2 mg/kg) |
25 |
78.1 |
12 |
57.1 |
182 [104-NA] |
0.03 |
| No (< 3.2 mg/kg) | 5 | 15.6 | 6 | 28.3 | 54 [40-NA] | |
* Missing data was 22.6%, 7.5% and 9.4% for ADE, duration of treatment with primaquine and primaquine dose adjusted by weight, respectively.
NA = not achieved.